HOME >> BIOLOGY >> NEWS
Targeting the adrenal gland could be key strategy against heart failure, Jefferson scientists show

(PHILADELPHIA) Scientists at the Center for Translational Medicine at Thomas Jefferson University in Philadelphia have staved off heart failure in animals by using gene therapy to shut down the adrenal glands excessive output of fight or flight hormones such as epinephrine and norepinephrine. By blocking GRK2, an important regulatory enzyme, they cut the hormone production that forces the heart to pump too hard, leading to heart failure. Such a novel approach targeting the adrenal gland in addition to the heart provides a potential new strategy against heart failure, and could lead to a new class of drugs.

The researchers, led by Walter Koch, Ph.D., W.W. Smith Professor of Medicine and director of the Center for Translational Medicine in the Department of Medicine at Jefferson Medical College, report their findings February 18, 2007, in an advance online publication in the journal Nature Medicine.

The emphasis has always been in treating right at the heart, says Stephen B. Liggett, M.D., director of the cardiopulmonary genomics program at the University of Maryland School of Medicine, who has written an accompanying editorial. Despite our best efforts, about half of all heart failure patients die within five years of diagnosis, so clearly something new is needed. These results add a completely new dimension to the way physicians might be able to intervene to improve heart failure therapy. When an individuals heart begins to fail, the sympathetic nervous system, attempting to compensate for the weakened heart, goes into overdrive, pumping out increasing levels of stimulants catecholamines such as epinephrine and norepinephrine, making a bad situation worse. The typical treatment beta blockers inhibit the beta adrenergic receptors on the heart, blocking the hormones that force the heart to work overtime.

Dr. Kochs group focused instead on the source of catecholamines the adrenal gland. It discovered that in heart failure,
'"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
18-Feb-2007


Page: 1 2

Related biology news :

1. Targeting key proteins of carcinogenesis
2. Targeting tumors the natural way
3. Targeting tau: Inflammation study suggests new approach for fighting Alzheimers
4. Best of both worlds -- Targeting a single gene could inhibit bone decay and stimulate bone growth
5. Targeting wolbachia, doxycycline reduces pathology of lymphatic filariasis
6. Targeting lung cancer
7. Targeting the dosage compensation complex
8. Targeting pancreatic cancer
9. Targeting a key enzyme with gene therapy reversed course of Alzheimers disease in mouse models
10. Targeting tumor growth
11. How the adrenal clock keeps the body in synch

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/2/2019)... ... November 01, 2019 , ... Stay on top of current ... device industries. Access to all webinars is free, so be sure to register today ... , Visit http://www.xtalks.com to see our upcoming webinars: , CLINICAL OPERATIONS , ...
(Date:10/30/2019)... Va. (PRWEB) , ... October 30, 2019 , ... ... offering from the Farm Credit Knowledge Center in which participants will learn about ... industry best practice relating to these technologies. , Participants will have the ...
(Date:10/30/2019)... ... October 30, 2019 , ... Amberdata Inc., the ... firms, including Fenbushi Capital, DF Capital, Rising Tide Fund, and HWVP. The ... to further accelerate its position as the leading data provider of institutional-grade blockchain ...
Breaking Biology News(10 mins):
(Date:10/22/2019)... , ... October 22, 2019 , ... ... has announced that its lead program, DBI-001, met its primary safety endpoints, with ... labeled phase 2a clinical trial for the treatment of interdigital tinea pedis (athlete’s ...
(Date:10/17/2019)... ... October 16, 2019 , ... ... easy-to-understand, web-based genetic counseling information, has published a new white paper that explores ... and provides guidance as to how patients and medical providers can be kept ...
(Date:10/10/2019)... Md. (PRWEB) , ... October 09, 2019 , ... ... announced Amy Abernethy, MD, PhD, Principal Deputy Commissioner, FDA, as a newly-confirmed keynote ... 27–30 October 2019 in Las Vegas, Nevada USA. , Dr. Abernethy, a hematologist/oncologist ...
(Date:10/10/2019)... (PRWEB) , ... October 10, 2019 , ... R3 Stem ... The next course is October 18-19th, 2019 in Las Vegas with spots still open. ... He completed training at several Ivy League universities including Cornell, Harvard and Dartmouth. He ...
Breaking Biology Technology:
Cached News: